Our current analysis evaluated the changes in individual and grouped plasma amino acid levels and related metabolites in a cohort of patients with T1D in response to (1) hyperglycemia, (2) SGLT2 inhibitor empagliflozin under clamped euglycemia, and (3) empagliflozin under clamped hyperglycemia. This evidence concerns the gene SLC5A2 and Hyperglycemia.